Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Patient with histologically proven CD20+ diffuse large B cell lymphoma (WHO Classification). * Age \>18 and \< 61 years, eligible for transplant. * Patient not previously treated. * With at least two prognostic factors of the Aa-IPI. * With a minimum life expectancy of 3 months. * Creatinin level ≤ 150mmol/l, total bilirubin level 30mmol/l and transaminases 2.5 maximum normal level, unless abnormalities are related to the lymphoma. * Neutrophils \> 1.5 G/l and platelets \> 100 G/l, unless if patient has a bone marrow infiltration. * Negative HIV, HBV and HCV serologies 4 weeks (except after vaccination). * Having previously signed a written informed consent. Exclusion Criteria: * Any other histological type of lymphoma. * Any history of treated or non-treated indolent lymphoma. * Central nervous system or meningeal involvement by lymphoma. * Contra-indication to any drug contained in the chemotherapy regimens. * Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. * Any serious active disease (according to the investigator's decision). * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study. * Pregnant or lactating women or women of childbearing potential not currently practicing an adequate method of contraception. * Adult patient under tutelage.